|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P306
|
A Protein Extract from Fermented Wheat Germ Promotes NK Cell-Mediated Lymphoma Eradication in Mouse Xenografts.
|
Gustavo Barisone1, Yunpeng Ma1, Mastewal Abuhay1, Robert O'Donnell1, Kathleen Lundeberg1, Sonia Gowda1, William Murphy2, Joseph Tuscano1
|
1University of California Davis, Sacramento, CA, USA 2University of California, Sacramento, CA, USA
|
Leukemia/Lymphoma | Immune adjuvant | NK/NK T cell
|
|
P307
|
Expression and function of PD-1 and TIM-3 in non-small cell lung cancer (NSCLC)
|
Jonathan Travers1, Krtisten McEachern1, Srimoyee Ghosh1, Sridhar Ramaswamy1, David Jenkins1
|
1TESARO Inc., Waltham, MA, USA
|
Antibody | Checkpoint blockade | Coinhibition | Cytokine | Gene expression | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P308
|
A PD-1 x CTLA-4 Bispecific DART® Protein with Optimal Dual Checkpoint Blockade and Favorable Tolerability in Non-human Primates
|
Alexey Berezhnoy1, Kurt Stahl1, Kalpana Shah1, Tim Gaynutdinov1, Gurunadh Chichili1, Daorong Liu1, Rebecca Johnson1, Ross La Motte-Mohs1, Jessica Hill1, Jonathan Li2, Sergey Gorlatov1, Valentina Ciccarone1, Ralf Alderson1, Hua Li1, James Tamura1, Jennifer Brown1, Jon Wigginton1, Ezio Bonvini1, Paul Moore1, Syd Johnson1
|
1Macrogenics, INC, Rockville, MD, USA 2Macrogenics, INC, South San Fancisco, CA, USA
|
Checkpoint blockade | Antibody | Immune suppression | T cell
|
|
P309
|
Treatment with heterodimeric IL-15 promotes effector T cell infiltration into tumors
|
Cristina Bergamaschi1, Konstantinos Dimas1, Dimitrios Stellas1, Bethany Nagy1, Shawn Jensen2, Bernard Fox2, Barbara Felber1, George Pavlakis1
|
1National Cancer Institute at Frederick, Frederick, MD, USA 2Earle A Chiles Research Institute, Portland Providence Cancer Center, Portland, OR, USA
|
Adoptive immunotherapy | Regulatory T cell (Treg) | Tumor microenvironment | Chemokine | Cytokine | Tumor infiltrating lymphocytes (TILs) | T cell
|
|
P310
|
CSF1/CSF1R signaling blockade triggers release of matrix-degrading proteases in mouse models
|
Stefan Bissinger1, Martina Schmittnaegel2, Ioanna Keklikoglou2, Michele De Palma2, Sabine Hoves1, Carola Ries1
|
1Roche Innovation Center Munich, 82377 Penzberg, Germany 2The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
|
Myeloid cells | Inflammation | Tumor microenvironment | Antibody | Monocyte/Macrophage | Biomarkers
|
|
P311
|
Clinical outcomes of PD-1 inhibition by PD-L1 expression level across malignancies in 204 consecutive patients in a real world oncology setting
|
Kenneth Byrd1, Tristan Hayes1, Mike Martin2, Lee Schwartzberg2, Ari Vanderwalde2
|
1University of Tennessee Health Sciences Center, Memphis, TN, USA 2West Cancer Center, Germantown, TN, USA
|
Antibody | Biomarkers | T cell
|
|
P312
|
AGEN2034, a novel anti-PD-1 antibody that combines effectively with CTLA-4 pathway blockade to enhance T cell activity
|
Dhan Chand1, David Savitsky1, Ana Gonzalez1, Christopher Clarke1, Andrea Schuster2, Elise E. Drouin1, Jeremy D. Waight1, Cornelia Mundt2, Gerd Ritter1, Taha Merghoub4, David Schaer4, Rikke B Homlgaard4, Roberta Zappasodi4, Marc van Dijk5, Jennifer S. Buell1, Jean-Marie Cuillerot1, Robert Stein1, Nicholas S Wilson1
|
1Agenus Inc., Lexington, MA, USA 2Former employee of Agenus Switzerland Inc., Basel, Switzerland 4Memorial Sloan Kettering Cancer Center, New York, NY, USA 5Agenus Switzerland Inc., Basel, Switzerland
|
Tumor infiltrating lymphocytes (TILs) | T cell | Immune suppression | Antibody | Checkpoint blockade | Coinhibition | Tumor microenvironment | Biomarkers | Cytokine | Costimulation
|
|
P313
|
In vivo Effect of Albumin Binding Domains Attached to Immune Modulators
|
Haomin Huang1, Keneshia Haenssen1, Anil Bhate1, Supriya Sanglikar1, John Baradei1, Shan Liu1, Senthil Kumar1, Zihao Cui1, Richard Hampton1, Robert Kramer1, John Cini1
|
1Sonnet BioTherapeutics, Cranbury, NJ, USA
|
Cytokine | Antibody
|
|
P314
|
Glioblastoma stem-like cell targeting antibodies identified using yeast display biopanning
|
Paul Clark1, Michael Zorniak1, Benjamin Umlauf1, Yongku Cho1, Eric Shusta1, John Kuo1
|
1University of Wisconsin - Madison, Madison, WI, USA
|
Biomarkers | Stem cell/cancer-initiating cell | Tumor antigens | Antibody | Solid tumors
|
|
P315
|
A bispecific fusion protein, ACDClx, can selectively activate T cells against glioblastoma cells in vitro
|
Rebecca Cook1, Sierra Bichler1, Andrew Diamos1, Braeden Schaefer1, Andrew Niemann1, Hugh Mason1, Tsafrir Mor1, Rachael Sirianni2, Joseph Blattman1
|
1Arizona State University, Tempe, AZ, USA 2Barrow Neurological Institute, Phoenix, AZ, USA
|
Targeted therapy | Antibody | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)
|
|
P316
|
Impact of anti- PD1 on TIL phenotype and function
|
Caitlin Creasy1, Cara Haymaker2, Marie-Andrée Forget2, Gopal Singh2, Coya Tapia2, Jeane Marie Painter2, Funda Meric-Bernstam2, Chantale Bernatchez2, Aung Naing2
|
1MD Anderson Cancer Center University of Texas Health Graduate School of Biomedical Sciences, Houston, TX, USA 2University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
Adoptive immunotherapy | Clinical trial | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Solid tumors
|
|
P317
|
In vivo efficacy and mechanism of action of anti-TIGIT monoclonal antibody CASC-674
|
Peter de Vries1, Robert Rosler1, Janelle Taylor1, Scott Peterson1
|
1Cascadian Therapeutics, Inc., Seattle, WA, USA
|
Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | Antibody | Immune suppression | Tumor infiltrating lymphocytes (TILs) | Inflammation | Tumor stroma | Monocyte/Macrophage | T cell
|
|
P318
|
Anti-tumor efficacy and enhancement of T cell effector functions by EOS084448, an antagonist anti-TIGIT antibody
|
Gregory Driessens1, Julia Cuende1, Sofie Denies1, Chaterine Hoofd1, Florence Lambolez1, Shruthi Prassad1, Virginie Rabolli1, Anthony Cooper2, Christophe Quéva1
|
1iTeos Therapeutics, Gosselies, Belgium 2Adimab, Lebanon, NH, USA
|
Costimulation | Immune tolerance | Regulatory T cell (Treg) | Tumor microenvironment | Checkpoint blockade | Coinhibition | Antibody | Immune suppression | Tumor infiltrating lymphocytes (TILs) | T cell
|
|
P319
|
Long-term disease-free survival (DFS) of metastatic melanoma (mM) and renal cell cancer (mRCC) patients following high-dose interleukin-2 (HD IL2)
|
Joseph Clark1, Brendan Curti2, Elizabeth Davis3, Howard Kaufman4, Asim amin5, Ajjai Alva6, Theodore Logan7, Ralph Hauke8, Gerald Miletello9, Ulka Vaishampayan10, Douglas Johnson3, Richard White5, Peter Wiernik11, Janice Dutcher12
|
1Loyola University, Maywood, IL, USA 2Providence Cancer Center, Portland, OR, USA 3Vanderbilt University, Nashville, TN, USA 4Rutgers University, New Brunswick, NJ, USA 5Carolinas Health Care System, Charlotte, NC, USA 6University of Michigan, Ann Arbor, MI, USA 7University of Indiana, Indianapolis, IN, USA 8Midwest Cancer Center, Omaha, NE, USA 9Hematology/Oncology Clinic, LLP, Baton Rouge, LA, USA 10Wayne State University, Detroit, MI, USA 11Cancer Research Foundation of New York, Chappaqua, NY, USA 12Cancer Research Foundation of New York, Bronx, NY, USA
|
Clinical study | Cytokine | Clinical trial | Solid tumors
|
|
P320
|
Targeting CD38 beyond haematological malignancies: a panel of anti-CD38 antibodies with unique functional properties.
|
Nina Eissler1, Pascal Merchiers1, Simone Filosto1, Rahul Chaitanya Khanolkar1, Beatriz Goyenechea1, Dominic Smethurst1, Kevin Moulder1, Sergio A. Quezada2, Anne Goubier1
|
1Tusk Therapeutics, Stevenage, United Kingdom 2UCL Cancer Institute, London, United Kingdom
|
Costimulation | MDSC | T cell lineages | Antibody | Targeted therapy | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Regulatory T cell (Treg) | NK/NK T cell
|
|
P321
|
Ibrutinib in combination with agonist αOX40 mAb and CTLA-4 blockade induces Eomes hi CD8 T cells and promotes tumor regression
|
Dana Emerson1, Michael Mcnamara2, Ian Hilgart-Martiszus2, Mohammad Farhad2, William Redmond2
|
1Oregon Health & Science University, Portland, OR, USA 2Earle A. Chiles Research Institute, Portland, OR, USA
|
Costimulation | Checkpoint blockade | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Cytokine | Targeted therapy
|
|
P322
|
Antitumor Effects of Radiation Combined with Intratumoral Anti-Tem8 mAb and IL2
|
Amy K. Erbe1, Kathryn Komro1, Arika Feils1, Mackenzie Heck1, Sabrina VandenHeuvel1, Manasi Mohan1, Peter M. Carlson1, Jacquelyn A. Hank1, Alexander Rakhmilevich1, Zachary S. Morris1, Amit Chaudhary2, Brad St. Croix3, Paul M. Sondel1
|
1University of Wisconsin-Madison, Madison, WI, USA 2Meso Scale Diagnostics, Rockville, MD, USA 3National Cancer Institute, Frederick, MD, USA
|
Cytokine | NK/NK T cell | Radiotherapy | Tumor antigens | Targeted therapy | Tumor microenvironment | Costimulation | Antibody | Angiogenesis | Antigen presenting cells
|
|
P323
|
Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies
|
Heather Torrey1, Audrey Defusco1, Danielle Baum1, Ziba Rahbar2, Michael Khodadoust2, Youn H. Kim2, Denise Faustman1
|
1Massachusetts General Hospital/Harvard Medical School, Charlestown, MA, USA 2Stanford University School of Medicine/Cancer Institute, Stanford, CA, USA
|
Immune tolerance | Regulatory T cell (Treg) | Tumor microenvironment | Antibody | T cell | Targeted therapy | Leukemia/Lymphoma
|
|
P324
|
Co-targeting of mesothelin and CD47 with bispecific antibodies for efficient elimination of solid tumors
|
Krzysztof Masternak1, Limin Shang1, Vanessa Buatois1, Stefano Majocchi1, Eric Hatterer1, Xavier Chauchet1, Valéry Moine1, Lucile Broyer1, Marie H. Kosco-Vilbois1, Nicolas Fischer1, Walter G. Ferlin1
|
1Novimmune S.A., Geneva, Switzerland
|
Tumor microenvironment | Checkpoint blockade | Targeted therapy | Antibody | Solid tumors | Monocyte/Macrophage
|
|
P325
|
Characterization of the anti-CTLA-4 antibody AGEN1884, including toxicology and pharmacology assessments in non-human primates
|
Randi Gombos1, Ana Gonzalez1, Mariana Manrique1, Dhan Chand1, David Savitsky1, Benjamin Morin1, Ekaterina Breous-Nystrom2, Christopher Dupont1, Rebecca Ward1, Cornelia Mundt3, Benjamin Duckless4, Hao Tang4, Mark Findeis1, Andrea Schuster3, Jeremy Waight1, Dennis Underwood1, Christopher Clarke1, Gerd Ritter5, Taha Merghoub6, David Schaer6, Marc van Dijk2, Jennifer Buell1, Jean-Marie Cuillerot1, Robert Stein1, Elise Drouin1, Nicholas WIlson1
|
1Agenus Inc., Lexington, MA, USA 2Agenus Switzerland Inc., Basel, Switzerland 3Former employee of Agenus Switzerland, Inc., Basel, Switzerland 4Former employee of Agenus Inc., Lexington, MA, USA 5Ludwig Institute for Cancer Research, New York, NY, USA 6Memorial Sloan Kettering Cancer Center, New York, NY, USA
|
Antibody | T cell | Cytokine | Immune toxicity | Immune monitoring | Checkpoint blockade
|
|
P326
|
Isoform specific TGF-β inhibition in combination with radiation therapy as a novel immune therapeutic approach to cancer therapy
|
Aditi Gupta1, Sadna Budhu1, Rachel Giese1, Jacques van Snick2, Catherine Uyttenhove2, Gerd Ritter3, Jedd Wolchok1, Taha Merghoub1
|
1Memorial Sloan Kettering, New York, NY, USA 2Ludwig Institute for Cancer Research Ltd Brussels Branch, Brussels, Belgium 3Ludwig Institute for Cancer Research, Ltd, New York, NY, USA
|
Tumor microenvironment | Targeted therapy | Solid tumors | Cytokine | Antibody | Immune suppression
|
|
P327
|
Intratumor injection of tumor-specific antibody and IL2 triggers in situ vaccination following local radiation therapy
|
Emily I. Guy1, Sara Busche1, Peter Carlson1, Clinton Heinze1, Ciara N. Schwarz1, Raghava N. Srirameneni1, Jasdeep Kler1, Michael M. Meagher2, Amy K. Erbe1, Jacquelyn A. Hank1, Alexander L. Rakhmilevich1, Paul M. Sondel1, Zachary S. Morris1
|
1University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 2St. Jude Children's Research Hospital/Children's GMP, LLC, Memphis, TN, Memphis, TN, USA
|
Antibody | Cytokine | Targeted therapy | Vaccine | Radiotherapy | T cell
|
|
P328
|
Therapeutic application of radiation-induced anti-tumor antibody
|
Tsuguhide Takeshima1, Raquibul Hannan1
|
1UT Southwestern Medical Center, Dallas, TX, USA
|
Dendritic cell | Radiotherapy | Antibody
|
|
P329
|
Dual blockade of PD1 and CTLA4 with bispecific antibody XmAb20717 promotes human T cell activation and proliferation
|
Michael Hedvat1, Matthew Bernett1, Gregory Moore1, Christine Bonzon1, Rumana Rashid1, Seung Chu1, Kendra Avery1, Alex Nisthal1, Umesh Muchhal1, John Desjarlais1
|
1Monrovia, CA, USA
|
Checkpoint blockade | Coinhibition | Targeted therapy | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs) | Antibody
|
|
P330
|
T cell immunotherapies trigger innate immunity and aseptic inflammation leading to potent anti-tumor and off-targets effects
|
Daniel Hirschhorn1, Jacob Ricca1, Bilel Gasmi1, Levi Mark Mangarin1, Olivier De Henau1, Sadna Budhu1, Yanyun Li1, Czrina Cortez1, Yang Xia1, Hong Zhong1, Cailian Liu1, Roberta Zappasodi1, Travis Hollmann1, Mario Lacouture1, Jean Albrengues2, Mikala Egeblad2, Wolchok Jedd1, Taha Merghoub1
|
1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
|
Immune adjuvant | Solid tumors | Immune toxicity | Tumor stroma | Tumor microenvironment
|
|
P331
|
Involvement of estrogen and progesterone in the modulation of indoleamine 2,3 dioxygenase - IDO – expression in cultured mammary carcinoma cells of female dog
|
Jose Roberto Kfoury Jr.1, Pedro Bianchi1, Flavia Ponce1, Rafael Leandro1, Tulio Yoshinaga1
|
1School of Veterinary Medicine and Animal Sciences, University of Sao Paulo, Sao Paulo, Brazil
|
Immune tolerance | Tumor microenvironment | Immune suppression | Tumor evasion
|
|
P332
|
Pre-clinical efficacy and tolerability of NKTR-255, a polymer-conjugated IL-15 for immuno-oncology
|
Peter Kirk1, Peiwen Kuo1, Murali Addepalli1, Takahiro Miyazaki1, Jane Gunther1, Laurie VanderVeen1, Ping Zhang1, Palakshi Obalapur1, Mekhala Maiti1, Amol Murkar1, Arunasree Lanka1, Werner Rubas1, Jonathan Zalevsky1
|
1Nektar Therapeutics, San Francisco, CA, USA
|
Dendritic cell | T cell lineages | Cytokine | NK/NK T cell | T cell
|
|
P333
|
MPL-5821, an ESM™-p38 MAPK Inhibitor, Enhances Tumor Immune Response and M1 Macrophage Polarization in a 3D Ex Vivo System Utilizing Fresh Tumor Microspheroids of Lung Cancer Patients
|
Melanie Mediavilla-Varela1, Melba Marie Page1, Jenny Kreahling1, Martin Perry2, David Moffat2, Scott Antonia1, Soner Altiok1
|
1Nilogen Oncosystems, Tampa, FL, USA 2Macrophage Pharma Limited, Windsor, United Kingdom
|
Myeloid cells | Monocyte/Macrophage | Tumor microenvironment | Targeted therapy | Cytokine | Gene expression | Tumor infiltrating lymphocytes (TILs) | Tumor evasion | Immune monitoring
|
|
P334
|
Inhibition of IDO activity by epacadostat (INCB024360) activates tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer and alleviates stromal immunosuppression
|
Melanie Mediavilla-Varela1, Melba Marie Page1, Jenny Kreahling1, Peggy Scherle2, Scott Antonia1, Soner Altiok1
|
1Nilogen Oncosystems, Tampa, FL, USA 2Incyte Corporation, Wilmington, DE, USA
|
Cytokine | Chemokine | Targeted therapy | Solid tumors | Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Gene expression | Tumor stroma | Immune suppression | Tumor evasion
|
|
P335
|
Characterization of a novel differentiated anti-CTLA-4 antibody (ADU-1604) in vitro and in vivo
|
Maaike Hendriks1, Joost Kreijtz1, Paul Vink1, David Lutje Hulsik1, Imke Lodewijks1, Astrid Bertens1, Jos van de Crommert1, Maurice Habraken1, Wout Janssen1, Judith Stammen-Vogelzang1, Weiwen Deng2, Laura Hix Glickman2, Meredith Leong2, Sarah McWhirter2, Thomas Dubensky2, Hans van Eenennaam1, Andrea van Elsas1
|
1Aduro Biotech Europe, Oss, Netherlands 2Aduro Biotech, Inc., Berkeley, CA, USA
|
Antibody | T cell | Regulatory T cell (Treg) | Checkpoint blockade
|
|
P336
|
Preclinical characterization of MGA012, a novel clinical-stage PD-1 monoclonal antibody
|
Ross La Motte-Mohs1, Kalpana Shah1, Jennifer G. Brown1, Ralph F. Alderson1, Doug Smith2, Sergey Gorlatov1, Valentina Ciccarone1, James K. Tamura1, Hua Li1, Leilei He1, Farha Vasanwala1, Jill R. Rillema2, Monica Licea2, Jessica Hill1, Christina Wolff1, Massimiliano Pascuccio1, Francine Z. Chen2, Yan Chen2, Anushka De Costa2, Ann Easton2, Alexey Berezhnoy1, Jonathan Li2, Jeffrey Nordstrom1, Scott Koenig1, Ezio Bonvini1, Syd Johnson1, Paul A. Moore1
|
1MacroGenics, Inc., Rockville, MD, USA 2MacroGenics, Inc., South San Francisco, CA, USA
|
Checkpoint blockade | Targeted therapy | T cell | Coinhibition
|
|
P337
|
Preclinical characterization of MGD013, a PD-1 x LAG-3 bispecific DART® molecule
|
Ross La Motte-Mohs1, Kalpana Shah1, Jennifer G. Brown1, Doug Smith2, Sergey Gorlatov1, Valentina Ciccarone3, James K. Tamura1, Hua Li1, Leilei He1, Farha Vasanwala1, Christine Shoemaker1, Jonathan Li2, Shereen Saini2, Jill R Rillema2, Monica Licea2, Jessica Hill1, Arin Whiddon1, Massimiliano Pascuccio1, Francine Z. Chen2, Anushka De Costa2, Ann Easton2, Peter Lung2, Kurt Stahl1, Jeffrey Nordstrom1, Scott Koenig1, Ezio Bonvini1, Syd Johnson1, Paul A. Moore1
|
1MacroGenics, Inc., Rockville, MD, USA 2MacroGenics, Inc., South San Francisco, CA, USA 3MacroGenics, Inc., Rockville, CA, USA
|
Checkpoint blockade | T cell | Targeted therapy | Coinhibition
|
|
P338
|
Combined IL-6 and CTLA4 blockade enhances CD8+ T cell infiltration via CXCR3 and limits growth of pancreatic cancer in murine models.
|
Christopher McQuinn1, Matthew Farren2, Thomas Mace1, Jacob Bowers3, Reena Shakya1, A. Brad Ferris2, Gregory Young1, William Carson, III1, Chrystal Paulos3, Bassel El-Rayes2, Gregory Lesinski2
|
1The Ohio State University, Columbus, OH, USA 2Winship Cancer Institute of Emory University, Atlanta, GA, USA 3Medical University of South Carolina, Charleston, SC, USA
|
Immune suppression | Checkpoint blockade | Antibody | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Tumor stroma | Cytokine | Tumor microenvironment | Chemokine
|
|
P339
|
Critical Role of Hematopoietic Progenitor Kinase 1 in Anti-tumor Immune Responses
|
Dan You1, Stephen Hillerman1, Jesse Swanson1, Ching-Ping Ho1, Anwar Murtaza1, Rukiye Eraslan1, Miguel Sanjuan1, John Hunt1, Luisa Salter-Cid1, Joshua Curtin2, Jinqi Liu1
|
1Bristol-Myers Squibb, Lawrence Township, NJ, USA 2Johnson & Johnson Pharmaceutical, Spring House, PA, USA
|
Cytokine | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs) | Checkpoint blockade | Inflammation
|
|
P340
|
In vitro effects and mechanism of hu14.18-IL2 immunocytokine against GD2 positive pediatric malignancies.
|
Holger Lode1, Maxi Zumpe1, Madlen Juettner1, Sascha Troschke-Meurer1, Evelyne Janzek2, Romana Schaefer2, Bettina Neuchrist2, Nikolai Siebert1, Hans Loibner2
|
1University Medicine Greifswald, Greifswald, Germany 2Apeiron Biologics, Vienna, Austria
|
Checkpoint blockade | Antibody | Pediatric tumors
|
|
P341
|
Peripheral Immunomodulatory Changes in Metastatic Renal Cell Carcinoma (mRCC) Patients Treated with Nivolumab
|
Lorena Almeida1, Manuel Maia1, Haejung Won1, Dayson Moreira1, Paulo Bergerot1, Marcin Kortylewski1, Sumanta Pal1
|
1City of Hope Comprehensive Cancer Center, Duarte, CA, USA
|
Biomarkers | Cytokine | Checkpoint blockade | T cell | Chemokine | Immune monitoring
|
|
P342
|
Blood in circulation, with intact cascade systems, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics
|
Erika Fletcher1, Mohamed Elthahir1, Frida Lindqvist2, Jonas Rieth1, Gunilla Törnqvist2, Justyna Leja-Jarblad1,2, Sara Mangsbo1,2
|
1Uppsala University, Uppsala, Sweden 2Immuneed AB, Uppsala, Sweden
|
Antibody | Chemokine | Immune monitoring | Immune toxicity | Cytokine
|
|
P343
|
Novel Immuno-Oncology Biologics Derived via Directed Evolution of IgSF Domains
|
Mark Maurer1, Ryan Swanson1, Michael Kornacker1, Steve Levin1, Chris Navas1, Chelsea Gudgeon1, Lawrence Evans1, Martin Wolfson1, Dan Ardourel1, Daniel DeMonte1, Joseph Kuijper1, Sean MacNeil1, Janhavi Bhandari1, Mark Rixon1, Stanford Peng1
|
1Alpine Immune Sciences, Inc., Seattle, WA, USA
|
Costimulation | Tumor microenvironment | Checkpoint blockade | Coinhibition | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Immune suppression
|
|
P344
|
Development and functional characterization of COM902, a novel therapeutic antibody targeting the immune checkpoint TIGIT
|
Sandeep Kumar1, Radhika Desai1, Hsin-Yuan Cheng1, Kyle Hansen1, Andy Drake1, Patrick Wall1, Kathryn Logronio1, Gady Cojocaru2, John Hunter1, Mark White1, Spencer Liang1, Maya Kotturi1
|
1Compugen USA, Inc., South San Francisco, CA, USA 2Compugen Ltd., Holon, Israel
|
Regulatory T cell (Treg) | Checkpoint blockade | Coinhibition | Targeted therapy | Antibody | NK/NK T cell | T cell | Tumor infiltrating lymphocytes (TILs) | Solid tumors
|
|
P345
|
Tumor protective effect of anti-MUC1.IgE in pancreatic cancer
|
Kamiya Mehla1, James A Grunkemeyer1, Ragupathy Madiyalakan2, Christopher F Nicodemus3, Michael A Hollingsworth1
|
1University of Nebraska Medical Centre, Omaha, NE, USA 2Oncoquest, Edmonton,, AB, Canada 3AIT Strategies, Franconia, NH, USA
|
Dendritic cell | Inflammation | Immune adjuvant | Tumor antigens | Solid tumors | T cell | TLR | Targeted therapy | Antibody | Checkpoint blockade
|
|
P346
|
Inhibition of MMP9 Yields Improved Effector T cell Responses in a PD1-Axis Refractory Model
|
Amanda Mikels-Vigdal1, Vladi Juric1, Chris O'Sullivan1, Erin Stefanutti1, Andrew Greenstein1, Maria Kovalenko1, Jeremiah Degenhardt1, Peng Yue1, Victoria Smith1
|
1Gilead Sciences, Inc, Foster City, CA, USA
|
Myeloid cells | Tumor microenvironment | Tumor stroma | Antibody | T cell | Monocyte/Macrophage | Immune suppression | Checkpoint blockade
|
|
P347
|
Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation
|
Gregory Moore1, Michael Hedvat1, Matthew Bernett1, Christine Bonzon1, Rajat Varma1, Suzanne Schubbert1, Sung-Hyung Lee1, Kendra Avery1, Rumana Rashid1, Alex Nisthal1, Liz Bogaert1, Irene Leung1, Seung Chu1, Umesh Muchhal1, John Desjarlais1
|
1Xencor, Inc., Monrovia, CA, USA
|
Antibody | Checkpoint blockade | Costimulation | Solid tumors | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P348
|
Dual Blockade of PD-L1 and LAG-3 with FS118, a Unique Bispecific Antibody, Induces T-cell Activation with the Potential to Drive Potent Anti-tumour Immune Responses
|
Matthew Kraman1, Natalie Fosh1, Katarzyna Kmiecik1, Katy Everett1, Carlo Zimarino1, Mustapha Faroudi1, Mateusz Wydro1, Alexander Koers1, Lesley Young1, Michelle Morrow1, Jacqueline Doody1, Mihriban Tuna1, Neil Brewis1
|
1F-star, Cambridge, United Kingdom
|
Immune tolerance | Regulatory T cell (Treg) | Checkpoint blockade | Coinhibition | Antibody | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P349
|
Molecular-targeted radiotherapy with an alkyl-phosphocholine analog leads toimmunomodulation in a syngeneic murine melanoma model
|
Suresh Veerankutty1, Peter Carlson1, Dana Baiu1, Clinton Heinze1, Alexander Boruch1, Amy Erbe1, Joseph Grudzinski1, Reinier Hernandez1, Bryan Bednarz1, Jamey Weichert1, Paul Sondel1, Zachary Morris1, Mario Otto1
|
1University of Wisconsin, Madison, WI, USA
|
Tumor microenvironment | Targeted therapy | Radiotherapy | Tumor infiltrating lymphocytes (TILs)
|
|
P350
|
Breast tumor suppression mediated by therapeutic expression of chemerin, an innate leukocyte chemoattractant
|
Russell Pachynski1, Ping Wang1, Brian Zabel2, Eugene Butcher2
|
1Washington University School of Medicine, St Louis, MO, USA 2Stanford University, Palo Alto, CA, USA
|
Chemokine | NK/NK T cell | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment | Targeted therapy | Immune adjuvant
|
|
P351
|
A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230
|
Lukas Pfannenstiel1, Jared Lopes2, Heather Losey2, Juan Alvarez2, Brian Gastman1
|
1Cleveland Clinic, Cleveland, OH, USA 2Alkermes, Inc., Waltham, MA, USA
|
Adoptive immunotherapy | Tumor antigens | Cytokine | T cell | Solid tumors | Tumor infiltrating lymphocytes (TILs)
|
|
P352
|
A novel CD73 blocking antibody restores T cell function and augments efficacy of Adenosine 2A Receptor (A2AR) inhibitor CPI-444
|
Emily Piccione1, Jenny Rudnick1, Barbara Daine-Matsuoka1, Glen Mikesell1, Richard Miller1, Ian McCaffery1
|
1Corvus Pharmaceuticals, Burlingame, CA, USA
|
Tumor microenvironment | Antibody | Immune suppression
|
|
P353
|
Discovery and pre-clinical development of an orally available small molecule antagonist targeting the CD47/SIRPα pathway for cancer immunotherapy
|
Pottayil Sasikumar1, Chennakrishna Gundala1, Wesley Balasubramanian1, Sudarshan Naremaddepalli1, Archana Bhumireddy1, Sandeep Patil1, Amit Dhudashiya1, Vijaysai Rayavarapu1, Anirudha Lakshminarasimhan1, Samiulla Dodheri1, Kiran Aithal1, Girish Daginakatte1, Murali Ramachandra1
|
1Aurigene Discovery Technologies Limited, Bangalore, India
|
Tumor microenvironment | Monocyte/Macrophage | Cytokine | Tumor evasion
|
|
P354
|
An orally bioavailable small molecule antagonist of VISTA and VSIG8 signaling pathways shows potent anti-tumor activity
|
Pottayil Sasikumar1, Sudarshan Naremaddepalli1, Raghuveer Ramachandra1, Nagesh Gowda1, Govardhan Alluri1, Manikyalarao Yerramsetti1, Sreenivas Adurthi1, Jiju Mani1, Rashmi Nair1, Amit Dhudashiya1, Samiulla- Dodheri1, Nagaraj Gowda1, Murali Ramachandra1
|
1Aurigene Discovery Technologies Limited, Bangalore, India
|
Tumor microenvironment | MDSC | Checkpoint blockade | Coinhibition | Tumor evasion
|
|
P355
|
Epigenetic modulation promotes tumor suppression and improves survival when combined with checkpoint inhibition in murine models of breast cancer
|
Evanthia Roussos Torres1, Hayley Ma1, Christine Rafie1, Brian Christmas1, Todd Armstrong1, Elizabeth Jaffee1
|
1Johns Hopkins University, Baltimore, MD, USA
|
Inflammation | Myeloid cells | Tumor microenvironment | Checkpoint blockade | Gene expression | Immune suppression | MDSC | Tumor infiltrating lymphocytes (TILs) | Clinical study | Monocyte/Macrophage
|
|
P356
|
Efficacy and Mechanism of Action of CXCR4 Inhibition in B16-OVA Melanoma Model
|
Ruchi Saxena1, Yan Wang2, James Mier1
|
1Beth Israel Deaconess Medical Center, Boston, MA, USA 2X4 Pharmaceuticals, Cambridge, MA, USA
|
Regulatory T cell (Treg) | Tumor microenvironment | Chemokine | Tumor infiltrating lymphocytes (TILs)
|
|
P357
|
The T-cell Growth Factor Cocktail IL-2/IL-15/IL-21 Enhances Expansion and Effector Function of Tumor-Infiltrating T cells in a Novel Process Developed by Iovance
|
Ian Frank1, Michelle Simpson-Abelson1, Michael Lotze1, Krit Ritthipichai1, Christopher Mosychuk1
|
1Iovance Biotherapeutics, Tampa Bay, FL, USA
|
Adoptive immunotherapy | Tumor infiltrating lymphocytes (TILs) | T cell | Solid tumors | Cytokine | Tumor microenvironment | Clinical trial
|
|
P358
|
Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
|
Lawrence Thomas1, Laura Vitale2, Thomas O'Neill2, Jenifer Widger2, Andrea Crocker2, Li-Zhen He2, Jeffrey Weidlick2, Karuna Sundarapandiyan2, James Storey1, Eric Forsberg1, Catherine Pilsmaker1, Lauren Gergel1, Elizabeth Do1, Joel Goldstein2, Henry Marsh1, Tibor Keler2
|
1Celldex Therapeutics, Needham, MA, USA 2Celldex Therapeutics, Hampton, NJ, USA
|
Antigen presenting cells | Dendritic cell | Immune contexture | Regulatory T cell (Treg) | MDSC | Antibody | B cell | Immune suppression | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P359
|
Effect of targeted anti-GD2/-CD16 Bispecific NK cell Engager (BiKE) with or without IL-15 super agonist ALT803 against GD2+ Neuroblastoma (NB) and Ewing Sarcoma (ES)
|
Aradhana Tiwari1, Dina Edani1, Janet Ayello1, Hing C. Wong2, Mitchell S Cairo1
|
1New York Medical College, Valhalla, NY, USA 2Altor BioscienceWebsiteDirections, Miramar, FL, USA
|
Antibody | Adoptive immunotherapy | Pediatric tumors | Tumor microenvironment | Targeted therapy | Tumor antigens | B cell | NK/NK T cell
|
|
P360
|
APX005M is a potent CD40 agonistic antibody capable of stimulating both innate and adaptive immune responses against cancer
|
Pia Björck1, Erin Filbert1, Ovid Trifan1, Xiaodong Yang1
|
1Apexigen Inc., San Carlos, CA, USA
|
Antigen presenting cells | Dendritic cell | Antibody | Monocyte/Macrophage | B cell | Cytokine | T cell
|
|
P361
|
A Novel T-Cell Engaging Bispecific Antibody Platform: Efficient In vivo Tumor Clearance with Minimal Cytokine Release
|
Nathan Trinklein1, Andrew Boudreau1, Ben Buelow1, Starlynn Clarke1, Kevin Dang1, Laura Davison1, Shelley Force Aldred1, Katherine Harris1, Suhasini Iyer1, Brett Jorgensen1, Heather Ogana1, Duy Pham1, Payal Pratap1, Udaya Rangaswamy1, Ute Schellenberger1, Harshad Ugamraj1, Omid Vafa1, Wim van Schooten1
|
1Teneobio, Menlo Park, CA, USA
|
Bioinformatics | Immune toxicity | Leukemia/Lymphoma | Tumor antigens | T cell | Antibody
|
|
P362
|
A novel assay using RNA aptamers to quantitate the fraction of IL2Ra (CD25) receptors occupied by IL2
|
Suresh Veeramani1, Sue Blackwell1, William Thiel1, Paloma Giangrande1, George Weiner1
|
1University of Iowa, Iowa City, IA, USA
|
Regulatory T cell (Treg) | Tumor microenvironment | Immune monitoring | Cytokine
|
|
P363
|
The OX40-CTLA-4 bispecific antibody, ATOR-1015, induces immune activation and anti-tumor effect
|
Niina Veitonmäki1, Karin Hägerbrand1, Mia Thagesson1, Doreen Werchau1, Karin Enell-Smith1, Anna Rosén1, Sara Frizell1, Anne Månsson-Kvarhammar1, Per Norlén1, Furebring Tina1, Peter Ellmark1
|
1Alligator Bioscience, Lund, Sweden
|
Antibody | Checkpoint blockade | Regulatory T cell (Treg) | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P364
|
Discovery and pharmacological characterization of JNJ-63723283, an anti-programmed cell death protein-1 (PD-1) antibody that blocks PD-1 function
|
Catherine Ferrante1, Nikki DeAngelis1, Gordon Powers1, Jocelyn Sendecki1, Hillary Millar2, Bethany Mattson1, Darlene Pizutti1, Christina Lourdes Mayer1, Weirong Wang1, Raymond Brittingham1, John Wheeler1, Linda Barone1, Rupesh Nanjunda1, Eilyn R. Lacy1, Sheng-Jiun Wu1, Jinquan Luo3, Enrique Zudaire1, Kathryn Packman1, Brian Geist1, Kevin Trouba1, Matthew V. Lorenzi1, Raluca I. Verona1
|
1Janssen Research & Development, Spring House, PA, USA 2Janssen Research & Development, Beerse, Belgium 3Janssen Resaerch & Development, Spring House, PA, USA
|
Tumor microenvironment | Antibody | Checkpoint blockade | T cell | Solid tumors | NK/NK T cell
|
|
P365
|
Development of JNJ-64158120, an anti-TIM-3 antibody to overcome innate and acquired mechanisms of resistance to PD-1 therapy
|
Nikki DeAngelis1, Gordon Powers1, Keri Dorn1, Matthew Chomo1, Douglas Dolfi1, Karla Wiehagen1, Douglas Marvel1, Bethany Mattson1, Darlene Pizutti1, Liam Campion1, Caitlin Morgan1, Brian Tomkowicz1, Nina Sabins1, Sandra Santulli-Marotto2, Jocelyn Sendecki1, John Wheeler1, Brian Whitaker1, Annmarie Winkis1, Linda Barone1, Deborah Kwok1, Eilyn R. Lacy1, Edmund Moon3, Steve Albelda3, Kathryn Packman1, Enrique Zudaire1, Matthew V. Lorenzi1, Raluca I. Verona1
|
1Janssen Research & Development, Spring House, PA, USA 2Alios BioPharma/Janssen Research & Development, South San Francisco, PA, USA 3University of Pennsylvania, Philadelphia, PA, USA
|
Antibody | Checkpoint blockade | NK/NK T cell | Solid tumors | T cell | Tumor microenvironment
|
|
P366
|
Anti–PD-L1 mAb treatment combined with cisplatin modulates intratumoral immune responses and promotes antitumor effects
|
Daiko Wakita1, Toshiki Iwai1, Masamichi Sugimoto1, Suguru Harada1, Miho Suzuki1, Kaname Yamamoto1
|
1Chugai pharmaceutical CO., LTD., Kamakura, Japan
|
Chemotherapy | Checkpoint blockade | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P367
|
X4P-001, an orally bioavailable CXCR4 antagonist, increases T cell infiltration in human metastatic melanoma
|
Robert Andtbacka1, Melinda Yushak2, Merrick Ross3, Kenneth Grossman1, Eleni Tsiroyanni4, Sarah Blanchette4, Lu Gan4, Yan Wang4, Mohammed Milhem5
|
1Huntsman Cancer Institute, Salt Lake City, UT, USA 2Winship Cancer Institute, Atlanta, GA, USA 3MD Anderson Cancer Center, Houston, TX, USA 4X4 Pharmaceuticals, Cambridge, MA, USA 5University of Iowa, Iowa City, IA, USA
|
Tumor microenvironment | Clinical study | Clinical trial | T cell
|
|
P368
|
eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, is an activator of anti-tumor immune response
|
Kevin Webster1, Rajesh Sharma1, Vikas Goel1, Craig Stumpf1, Jocelyn Stauton1, Peggy Thompson1, Gary Chiang1, Yichen Xu2, Hyun Yong Jin2, Davide Ruggero2
|
1eFFECTOR Therapeutics, San Diego, CA, USA 2Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
|
Tumor microenvironment | Cytokine | Adoptive immunotherapy | T cell lineages | Dendritic cell | Targeted therapy | Checkpoint blockade | Clinical trial | T cell | Tumor infiltrating lymphocytes (TILs)
|
|
P369
|
Analysis of the TIGIT/PVRIG axis in human cancers to support indication selection and biomarkers for COM701 and COM902
|
Sarah Whelan1, Ling Leung1, David Bernardos1, John Hunter1, Mark White1, Spencer Liang1
|
1Compugen USA, Inc., South San Francisco, CA, USA
|
Tumor microenvironment | Tumor infiltrating lymphocytes (TILs) | Solid tumors | Antibody | Checkpoint blockade | Targeted therapy | T cell | NK/NK T cell
|
|
P370
|
Enhancement of tumor specific immunity by activation of CD40 through a bispecific molecule targeting CD40 and a tumor surface antigen
|
Shiming Ye1, Diane Yu1, Nicole Belmar1, Donghee Choi1, Debra Chao1, Mien Sho1, Han Kim1, Jean Cabel2, Danying Song2, Kelley Hiser2, John Harlan2, Catherine Zhang1, Yuni Fang1, Steve Keller1, Alan Wahl3, Patricia Culp4, Diane Hollenbaugh1
|
1AbbVie Biotherapeutics Inc., Redwood City, CA, USA 2AbbVie Inc., North Chicago, IL, USA 3Former AbbVie Employee, Del Mar, CA, USA 4Former AbbVie Employee (currently working at Alector Inc.), South San Francisco, CA, USA
|
Antibody | Antigen presenting cells | Costimulation | Solid tumors | Targeted therapy | Tumor antigens | T cell | Immune contexture | Immune toxicity
|